UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.
Werewolf Therapeutics, a US-based cancer biotherapeutics developer, completed a $72m series B round on Thursday backed by UPMC Enterprises, the investment arm of healthcare provider University of Pittsburgh Medical Center (UPMC).
RA Capital Management led the round, while healthcare investment firm Deerfield Management and Taiho Ventures, the corporate venturing division of pharmaceutical firm Taiho Pharmaceutical, also took part.
HBM Healthcare Investments, Soleus Capital, Adage Capital, Sphera Healthcare, CaaS Capital, MPM Capital, Longwood Fund, Arkin Bio Ventures and…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
